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Gabapentin has been administered in placebo-controlled studies with a thrice daily (T.I.D.) schedule, because of its short half-
life. However, clinical efficacy does not seem strictly related to plasma levels: a twice daily (B.I.D.) schedule might therefore be
possible. The aim of our study was to verify if the conversion from a T.I.D. to a B.I.D. regimen affected the efficacy and safety of
gabapentin therapy. Out of 171 patients treated with add-on gabapentin, we selected 29 stable responders, who were followed for
three months with a T.I.D. schedule and then switched to B.I.D. regimen for further three months. Seizure number, side-effects
and trough plasma levels of gabapentin were collected during both periods. Gabapentin mean dose was 2117.2 mg/day. Mean
number of seizures/months was: 4.2 at baseline, 1.0 during the T.I.D., and 0.9 during the B.I.D. period. Mean trough plasma
level of gabapentin was 5.9 µg/ml during the T.I.D. and 5.2 µg/ml during the B.I.D. period. Twelve side-effects were reported
by 11 patients during the T.I.D. and 6 by 5 patients during the B.I.D. period., sedation and vertigo were the most frequent in both.
Results of our study suggest that gabapentin can be administered safely and effectively either with a T.I.D. and a B.I.D. regimen.
c© 2000 BEA Trading Ltd
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INTRODUCTION
Gabapentin (GBP) is an anticonvulsant with a
favourable pharmacokinetic profile, characterized by
no binding to plasma proteins and no interactions with
other antiepileptic drugs (AEDs).
The precise mechanism of the antiepileptic action
of GBP is still unknown. Although structurally related
to the gamma aminobutyric acid (GABA) neurotrans-
mitter, GBP does not bind to GABA receptors and
does not influence neural uptake of GABA or have
any significant effect on GABA transaminase activity.
Possible mechanisms of action include biochemical
effects enhancing the ratio of GABA to glutamate in-
side the neurons and the enhancement of nonsynaptic
GABA release1. These cellular actions of GBP are not
completely understood, but the delayed peak of GBP
antiepileptic effects in animal models, compared to
the peak in plasma levels2 suggests that they may play
an important contribute to the therapeutic effect of the
drug.
GBP inhibits voltage-dependent sodium currents
and binds to a calcium channel in the brain3, but the
relevance of this actions to GBP anticonvulsant effects
has still to be clarified.
Three pivotal, placebo-controlled, add-on trials4–6
demonstrated a dose-response effect at dosages rang-
ing from 600 to 1.800 mg/day suggesting increasing
efficacy with increasing dose. In postapproval clin-
ical studies, the efficacy and safety of high GBP
dosages was investigated both as long-term and
short-term treatment. The drug was well tolerated
at all dosages, up to 4800 mg/day and a higher
percentage of patients, compared to early studies,
reached either satisfactory or complete seizure con-
trol7–10.
Pharmacokinetic studies11, 12 have shown that GBP
plasma concentrations are essentially proportional to
dosages up to 1800 mg daily, above which they still
increase, but not in a linear way13, 14.
GBP plasma concentrations have also been mea-
sured in several clinical studies. Sivenius et al. 15
found a correlation between efficacy and serum lev-
els starting at GBP concentration of 2 µg/ml, while a
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Fig. 1: Trough plasma levels of GBP (µg/ml)–(mean ± standard deviation).
similar correlation was not found in other studies8, 9.
A steady, even if not linear, increase in plasma lev-
els with increasing dosages, up to 6000 mg/day, was
found in all the studies where GBP plasma levels have
been measured7–9, 15, 16.
A drawback in the pharmacokinetic profile of GBP
is its short half-life, which suggests the need for thrice
daily (T.I.D.) administration which can decrease pa-
tient compliance, especially when the drug is used as
an add-on to other AEDs.
Empirically, however, in clinical practice, GBP is
often administered twice daily (B.I.D.), but no stud-
ies have been performed so far to explore whether the
switch from T.I.D. to B.I.D. administration causes a
decrease in efficacy or a worsening of side-effects due
to higher individual doses.
The aim of our study was to verify the feasibility of
this switch in a selected population of patients and to
assess trough GBP plasma levels under the two differ-
ent schedules of administration.
MATERIALS AND METHODS
Selection criteria and study design
This study adopted a single centre, add-on, open de-
sign.
In a previous, multicentre study, whose results have
been reported in abstract form17, we selected 171 pa-
tients, aged at least 12 years, with definite partial
epilepsy, and persistent simple and complex partial
seizures with or without secondary generalization, al-
ready in therapy with 1 or more AEDs in an adequate
dose.
A retrospective three-months baseline period was
obtained in all the patients in order to assess a base-
line seizure frequency, and then GBP given T.I.D. was
added into their current AED therapy.
Out of this sample, we selected 29 stable responders
(>50% reduction in seizure frequency versus baseline
after GBP add-on), and in whom the dose they were
currently taking was considered as their optimal GBP
therapeutic dose.
The number of seizures/month, assessed during the
three-month period before GBP introduction, was con-
sidered as baseline.
The optimal GBP dose was administered with a
T.I.D. regimen for three months: patients registered all
their seizures and any adverse drug reactions in a daily
diary. Thereafter the patients were switched to receive
the same dose of GBP with a B.I.D. regimen and fol-
lowed for another three months period.
Trough plasma levels gabapentin
Concentrations of GBP in plasma were determined at
the end of the first month of each T.I.D. and B.I.D.
period and trough levels were calculated.
GBP concentrations were measured by gas
chromatography-mass spectrometry18. The concen-
tration of gabapentin was obtained using a cali-
bration curve constructed with the peak area ratio
between gabapentin (m/z 210) and internal stan-
dard, 5α-cholestane (m/z 217). The calibration curve
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Table 1: GBP optimal theraputic dose, trough GBP plasma level, monthly seizure frequency and side-effects in T.I.D. and B.I.D.
period for all patients.
No. GBP GBP GBP Seizures/ Seizures/ Seizures/ Side-effects Side-effects
patient dose plasma plasma month month month T.I.D. B.I.D.
mg/day level level Baseline T.I.D. B.I.D.
T.I.D. B.I.D.
1 1200 4.1 2.9 3 0 1
2 1800 5.2 5.4 4 2 1
3 2400 6.3 7.2 6 1 0 Nausea
4 3200 8.1 8.6 8 3 2 Abdominal discomfort
5 1800 7.0 5.9 3 1 2
6 2400 5.9 4.5 2 0 1 Vertigo
7 1800 4.9 4.1 2 0 0 Sedation
8 1200 4.6 5.4 6 2 3 Sedation
9 2400 8.2 7.5 7 1 2
10 3200 5.4 6.0 4 0 0 Abdominal discomfort
11 1800 6.1 5.3 6 1 1
12 1800 2.8 3.4 2 0 0 Sedation Sedation, depression
13 2400 7.1 6.9 3 0 1 Sedation Sedation
14 3200 4.9 4.1 4 0 2
15 3200 7.8 8.3 6 1 0 Nausea
16 3200 6.9 6.1 3 1 0
17 1800 5.3 7.0 6 2 2
18 2400 6.4 3.3 4 0 0
19 3200 8.1 4.9 3 0 2 Hypersalivation sedation
20 1200 3.5 4.3 5 1 0 Sedation
21 1800 3.2 5.3 4 2 0
22 2400 4.1 3.1 2 0 0 Sedation
23 1200 2.0 2.9 3 0 2
24 1600 4.8 4.6 6 2 3 Vertigo Vertigo
25 1600 5.6 7.2 2 3 1
26 1800 2.3 3.9 3 1 0
27 1200 1.9 2.7 3 0 0
28 1800 1.9 2.7 2 0 0
29 2400 5.0 3.1 9 4 1
showed a good linearity from 0.5 to 15 µg/ml
(y = 0.314x + 0.131, r = 0.986).
The lower limit of detection is 0.08 µg/ml (sig-
nal/noise ratio 5 : 1). Imprecision was calculated by
multiple measurements of gabapentin (n = 10) on the
same day and on different days and the coefficients of
variation resulted respectively in 4.8% and 7.3% for
concentration ranging between 1 and 8 µg/ml.
Data analysis
Due to small data sets, for which assumptions about
the distribution of the variables being analysed and
about the homogeneity of variances cannot be vali-
dated adequately, distribution free statistical methods
have been chosen for the analysis.
Two tailed tests were used for the statistical analysis
at a level of significance fixed at α = 0.05.
All the variables were analysed descriptively by
means of the usual methods: mean, standard devia-
tion, minimum and maximum, absolute and relative
frequencies.
The effect of the GBP introduction on the monthly
seizure frequency, either T.I.D. or B.I.D. versus base-
line, has been analysed by Friedman’s Test; the differ-
ence in seizures rate between the T.I.D. and the B.I.D.
period has been analysed by Wilcoxon’s Test. The ef-
fect of the switch from T.I.D. to B.I.D. on the GBP
plasma levels has been analysed by the paired samples
T Test. Fisher’s exact test was used to compare the fre-
quencies of side-effects observed during the two treat-
ment periods.
RESULTS
Twenty-nine patients were enrolled and all finished the
study. There were 14 males and 15 females, mean age
37.8 years (range 16–64). Twenty-five patients (86%)
had simple and complex partial seizures only and 4
(14%) had secondarily generalized seizures as well.
The mean disease duration was 12.8 years. The opti-
mal mean daily dose of GBP was 2117.2 mg (range
1200–3200 mg/day). All patients were on polyphar-
macy. The mean number of concomitant AED was 1.7,
10 patients received 1 concomitant AED and 19 re-
ceived 2 concomitant AEDs. The most frequently pre-
scribed concomitant AED was carbamazepine (24 pa-
tients), followed by phenobarbitone (12 patients),
phenytoin (6 patients), valproic acid (3 patients), lam-
otrigine (2 patients) and vigabatrin (1 patient). Table 1
reports GBP dose, trough GBP plasma levels, mean
monthly seizure frequency and side-effects at baseline,
during the T.I.D. and B.I.D. periods for each patient.
The mean number of seizures/month was 4.2 ±
1.9 SD at baseline, 1.0 ± 1.1 in the T.I.D. period and
0.9±1.0 in the B.I.D. period (GBP add-on versus base-
line, Friedman Test P = 0.001; B.I.D. versus T.I.D.,
Wilcoxon Test, P = 0.1).
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Mean trough plasma levels of GBP did not change
significantly from the T.I.D. period (5.4 ± 1.9 µg/ml)
to the B.I.D. period (5.1 ± 1.8 µg/ml) (T Test, P =
0.72; C.I. 95% of the difference: −0.41, 0.59) and
ranged from 3.2 µg/ml to 6.9 µg/ml in the T.I.D. pe-
riod and from 3.6 µg/ml to 6.3 µg/ml in the B.I.D.
period (Fig. 1).
Twelve side-effects were reported by 11 patients
during the B.I.D. period and 6 side-effects were re-
ported by 5 patients during the T.I.D. period (χ2, P =
0.141). The most frequently reported side-effect dur-
ing both periods was sedation.
DISCUSSION
In this study we assessed the effect of switching
GBP administration from a T.I.D. schedule to a B.I.D.
schedule upon monthly seizure rate, side-effects and
trough GBP plasma levels.
We decided to make the switch in 29 patients who
were known stable GBP responders, so that the opti-
mal therapeutic GBP dose had already been found and
any possible effect related just to the switch could be
more easily detected.
GBP has been approved for T.I.D. administration
because of its short half-life; moreover, if a high daily
dose is divided in two instead of three single doses,
absorption could decrease, thus impairing the achieve-
ment of adequate plasma levels or, if absorption is
maintained, single doses could become too high, caus-
ing more side-effects. Hypothetical consequences of
such a switch could be either an increase in seizure
frequency or the worsening of side-effects.
The two different administration schedules were
examined over a three months period, which can be
considered sufficient to detect a possible change in
seizure rate or in side-effects due to different GBP
plasma levels.
The results of our study did not show any difference
in the considered parameters between the two admin-
istration regimens.
What is more important in our results is that effi-
cacy in seizure control was maintained without an in-
crease in side-effects and independently of plasma lev-
els. These results confirm the possibility of titrating
GBP doses without checking plasma levels, which are
unpredictive of response, and suggest that GBP can be
administered B.I.D. as safely and effective as T.I.D.
with possible advantage to patient compliance.
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